康众医疗(688607) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 70,466,638.51, representing a year-on-year increase of 65.52%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 4,408,843.35, an increase of CNY 5,228,735.1 compared to the same period last year[11] - The net profit attributable to shareholders for the year-to-date period was CNY 3,297,845.75, up CNY 6,889,935.67 year-on-year[11] - The basic and diluted earnings per share for Q3 2023 were both CNY 0.05, compared to CNY 0.04 for the same period last year[6] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for the current period is ¥1,000,637.03, an increase of ¥3,984,744.25 compared to the same period last year[12] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for the year-to-date period is -¥6,369,408.34, an increase of ¥6,091,445.66 compared to the same period last year[12] - In Q3 2023, the company reported a net profit of CNY 3,391,715.57, a significant recovery from a net loss of CNY 3,597,401.60 in the same period last year[26] - The total profit for Q3 2023 was CNY 2,630,915.73, compared to a total loss of CNY 4,171,961.79 in Q3 2022, indicating a turnaround in financial performance[26] - The company's operating profit for Q3 2023 was CNY 2,414,293.84, a recovery from an operating loss of CNY 4,458,677.46 in the previous year[26] Cash Flow and Liquidity - The company reported cash flows from operating activities of CNY 10,667,195.08 for the year-to-date period[6] - The net cash flow from operating activities for the current period is ¥10,667,195.08, an increase of ¥45,002,005.89 compared to the same period last year, primarily due to improved collection of receivables and reduced material procurement expenditures[12] - The cash flow from operating activities for the first nine months of 2023 was CNY 10,667,195.08, a significant improvement from a negative cash flow of CNY 34,334,810.81 in the same period of 2022[29] - The company's cash and cash equivalents decreased to ¥147,853,156.24 from ¥198,253,632.14, a decline of 25.4%[20] - The company’s cash and cash equivalents at the end of Q3 2023 stood at CNY 147,853,156.24, compared to CNY 126,065,735.02 at the end of Q3 2022, reflecting improved liquidity[30] Research and Development - Research and development expenses totaled CNY 11,516,536.33 for Q3 2023, accounting for 16.34% of operating revenue, a decrease of 9.40 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2023 amounted to ¥34,762,082.95, slightly increasing from ¥33,373,140.73 in 2022[25] Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 931,431,601.12, reflecting a 3.18% increase from the end of the previous year[6] - The company's total assets as of September 30, 2023, were ¥931,431,601.12, compared to ¥902,683,287.61 at the end of 2022, indicating growth of 3.2%[22] - Current assets totaled ¥790,878,860.23 as of September 30, 2023, down from ¥812,134,833.48 at the end of 2022, a decrease of 2.5%[20] - The company's total liabilities increased to ¥83,484,033.87 as of September 30, 2023, compared to ¥58,526,453.43 at the end of 2022, representing a rise of 42.5%[21] Shareholder Information - The top ten shareholders hold a total of 6,108 shares, with the largest shareholder, Liu Jianqiang, holding 12,810,000 shares, representing 14.54% of the total[14] - The second-largest shareholder, Zhongxin Suzhou Industrial Park Venture Capital Co., Ltd., holds 8,965,203 shares, accounting for 10.17%[15] Strategic Focus - The company attributed revenue growth to the successful implementation of new products and technologies, as well as improved customer satisfaction and new client acquisition[11] - The company has improved its cost accounting model, leading to more effective cost control and a stabilization of gross profit margins[12] - The company has implemented a strategy to optimize cost management and enhance operational profitability through improved budgeting systems[12] - The company is focused on market expansion and new product development as part of its growth strategy moving forward[12] Performance Metrics - The weighted average return on equity for Q3 2023 was 0.52%, an increase of 0.61 percentage points compared to the same period last year[6] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.04, recovering from a loss of CNY 0.04 per share in Q3 2022[27] - The company experienced a decrease in revenue from sales of goods and services, totaling CNY 163,371,865.08 in the first nine months of 2023, down from CNY 173,395,683.98 in the same period of 2022[29]